|
Recent Products |
|
 |
|
|
|
Biodefense
Since 2002 Planet
Biotechnology has placed special
emphasis on developing antibody
therapeutics for emerging diseases, and
biodefense countermeasures to known
bio-warfare agents, including toxins,
viruses and bacteria. With support from
the National Institute of Allergy and
Infectious Diseases (NIAID), we have
developed an immunoadhesin for treatment
and prevention of anthrax (PBI-220) and
have tested it successfully in
anthrax-infected monkeys as a
therapeutic with an 80% survival rate
when treatment is started after disease
symptoms appear. We have conducted a
pre-IND meeting with FDA and are seeking
funding for the clinical testing of
PBI-220.
Emerging
Diseases
Middle East Respiratory
Syndrome (MERS) is a recently emerged
disease caused by the MERS coronavirus
(MERS-CoV) endemic to the Arabian
Peninsula. It has already appeared in
seven Middle Eastern countries and has
traveled to European countries and
South Korea as well. MERS-CoV causes a
pneumonia-like disease that has a
fatality rate approaching 40%. We have
created and produced in green plants
an immunoadhesin (DPP4-Fc) that has
improved binding to MERS-CoV and have
shown that it prevents the virus from
infecting human lung cells in culture.
In June 2015 we were awarded a Phase
II SBIR grant from NIAID to support
development of this candidate
immunoadhesin. We will be testing
DPP4-Fc in animal models of MERS-CoV
based on our encouraging in vitro
data.
Protein expression and
purification services
We have considerable
experience expressing human and
chimeric IgA and IgG antibodies,
immunoadhesins, nanobodies, and other
proteins.
Planet Biotechnology is a DARPA
contractor (contract no.
HR001113D-0004) for production of
recombinant proteins in Nicotiana benthamiana.
Our proprietary codon optimization
method enables unprecedentedly high
expression levels of recombinant
proteins in both transiently and stably
transformed tobacco plants. We have
achieved expression of IgG1 at levels up
to 3 grams/kg of plant biomass after
vacuum-assisted agroinfiltration. These
high levels of expression, along with
our proprietary purification methods,
result in high product yield and purity.
We have research quantities of the
following proteins available:
-
CMG2-Fc: immunoadhesin for treatment
and prevention of anthrax, it consists of
human extracellular CMG2 fused to human
Fc
-
TEM8-Fc: human extracellular TEM8
domain fused to human Fc
-
BSG-Fc: human
extracellular basigin domain (P. falciparum Rh5
receptor)
fused to human Fc
-
AtCry1: Full-length, FAD-loaded
Arabidopsis thaliana cryptochrome 1
Customer
testimonial:
“Thank you for the fantastic [AtCry1]
samples. They have been used to reveal
very interesting reactivity in
cryptochromes in regard to the
amplification mechanism for boosting
magnetic sensitivity” (Chemistry
Department, Oxford University)
To find out more about our proteins
and services, please email us at info@planetbiotechnology.com
|
